A randomized, double-blind, placebo-controlled, multiple-dose, parallel-group clinical trial to assess the effects of teduglutide on gastric emptying of liquids in healthy subjects

What Was Tested

Researchers studied Teduglutide (GLP-2 analog) in this randomized controlled trial publication.

Teduglutide, a recombinant analog of human glucagon-like peptide (GLP)-2, is a novel therapy recently approved for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support.

Previous studies assessing the effect of GLP-2 on gastric emptying in humans have yielded inconsistent results, with some studies showing no effect and others documenting a GLP-2-dependent delay in gastric emptying.

Who Took Part

According to the abstract, 36 subjects were involved.

The age groups tagged for this paper are young adults and adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and parallel-group.

Random assignment meant chance, not the researchers, decided who got Teduglutide (GLP-2 analog) and who got the comparison, which limits bias.

Neither the subjects nor the staff measuring them knew who was on Teduglutide (GLP-2 analog), so expectations could not easily colour the readings.

Some subjects received a placebo instead of Teduglutide (GLP-2 analog), giving a reference point.

Groups ran in parallel: each of the subjects stayed in one arm throughout.

What Was Measured

Previous studies assessing the effect of GLP-2 on gastric emptying in humans have yielded inconsistent results, with some studies showing no effect and others documenting a GLP-2-dependent delay in gastric emptying.

The subject headings attached to it are Absorption, Acetaminophen, Area Under Curve, Gastric Emptying, Gastrointestinal Agents and Peptides.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teduglutide (GLP-2 analog) in 36 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2014 (BMC gastroenterology), a journal based in England.

More context: the Teduglutide (GLP-2 analog) compound page, all human trials.